Intelligence Feed event · Equity · 2026-09-06

    Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry

    Question

    Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry

    Direct answer

    Intuitive Surgical equity has corrected 40% from peak valuation levels following a moderation in robotic surgical console installations. Competitive robotic platforms from Medtronic and Johnson & Johnson are increasingly competing for hospital capital expenditure budgets. The company maintains structural downside support through its installed base, where instruments, accessories, and maintenance generate 75% of total top-line revenue.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-06
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry”, revision 1, evidence through 2026-09-06. https://marketontology.com/market-events/2026-09-06/intuitive-surgical-pulls-back-40-on-medtronic-and-j-j-rivalry-868835

    EQUITY
    Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
    Intuitive Surgical equity has corrected 40% from peak valuation levels following a moderation in robotic surgical console installations. Competitive robotic platforms from Medtronic and Johnson & Johnson are increasingly competing for hospital capital expenditure budgets. The company maintains structural downside support through its installed base, where instruments, accessories, and maintenance generate 75% of total top-line revenue.
    ISRGMDTJNJ
    Impact
    67
    SEP 6
    SIG
    80%
    ISRGMDTJNJ
    Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
    Intuitive Surgical equity has corrected 40% from peak valuation levels following a moderation in robotic surgical console installations. Competitive robotic platforms from Medtronic and Johnson & Johnson are increasingly competing for hospital capital expenditure budgets. The company maintains structural downside support through its installed base, where instruments, accessories, and maintenance generate 75% of total top-line revenue.
    → Capital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows.
    Impact
    Intuitive Surgical equity has corrected 40% from peak valuation levels following a moderation in robotic surgical console installations. Competitive robotic platforms from Medtronic and Johnson & Johnson are increasingly competing for hospital capital expenditure budgets. The company maintains structural downside support through its installed base, where instruments, accessories, and maintenance generate 75% of total top-line revenue.
    Affected
    ISRGMDTJNJ
    Transmission
    Capital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ISRGmultiple re-rating from slowing system unit sales balanced by 75% recurring service cash flowMixed1-4wISRG stock down 40% amid slower da Vinci sales growth while maintaining 75% recurring revenue.
    MDTmarket share gain in robotic surgical device capital budgetsUp1-4wMedtronic competitive pressure is cited as taking market share in surgical robotics.
    JNJmedtech surgical robotics expansion driving incremental medtech division growthUp1-4wJohnson & Johnson identified as key competitor challenging Intuitive Surgical market dominance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUpdisagreed275.23 2026-09-04-2.22%-3.24%-8.10%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month